The EIF4G3 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the MES-OV human ovarian endometrioid carcinoma cell line, engineered for disruption of the EIF4G3 gene. This heterogeneous knockout pool enables functional studies of EIF4G3 without clonal selection biases. EIF4G3 encodes a scaffold protein of the eIF4F complex essential for cap-dependent translation initiation. The loss-of-function model facilitates investigation of translation control in oncogenic signaling and is intended for advanced biomedical research.
The MES-OV cell line models ovarian endometrioid carcinoma, a subtype of epithelial ovarian cancer, and exhibits hallmark activation of PI3K/AKT and mTOR pathways that drive aberrant cell growth. This well-characterized line is widely employed for studying oncogenic signaling, chemoresistance, and targeted therapy. These cells display anchorage-independent growth and respond to growth factors, making them a robust platform for signal transduction studies. Editing EIF4G3 in MES-OV cells provides a disease-relevant background to examine how translation initiation contributes to ovarian cancer pathogenesis.
EIF4G3 serves as a central scaffold in the eIF4F complex, bridging eIF4E (cap-binding protein) and eIF4A (RNA helicase), and recruiting the 40S ribosomal subunit via eIF3. This assembly is regulated by mTORC1, which phosphorylates 4E-BP1 to release eIF4E, thereby promoting complex formation. Upstream, mTORC1 is activated by PI3K/AKT and MAPK pathways in response to growth factors. EIF4G3 also interacts with PABP to circularize mRNA, enhancing translation. Downstream, EIF4G3-driven translation increases synthesis of oncoproteins such as MYC, CCND1, and BCL2, particularly from mRNAs with structured 5′ UTRs. Knockout disrupts these processes, reducing oncogenic protein production.
In MES-OV cells, EIF4G3 knockout disrupts eIF4F complex assembly, leading to diminished synthesis of MYC, CCND1, and BCL2. This loss attenuates cell proliferation, measured by colony formation and MTT assays, and enhances apoptosis. The model offers a powerful system to investigate translation-dependent oncogenic mechanisms and to evaluate therapeutic strategies that inhibit the translation machinery in ovarian cancer.
Researchers can utilize these polyclonal knockout cells for western blotting, polysome profiling, dual-luciferase translation reporter assays, and RNA-seq to characterize translation control. Functional assays such as MTT proliferation, colony formation, and apoptosis assays are suitable for phenotypic analysis. Applications include cancer biology, translational research, ovarian cancer modeling, drug target validation, and oncoprotein synthesis studies. For further details, contact Ascent Research.
